Provider review · Updated September 30, 2026
Lavender Sky Health tirzepatide records: separate the custom plan and brand fee
Keep custom-plan prepayment, the medicine-excluding brand service and consultation charges attached to their actual records.
Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.
Lavender Sky Health's pricing page and FAQ describe several arrangements that should not be squeezed into a single monthly figure. A custom compounded plan, a brand-name service plan and a consultation fee each attach money to a different part of care. Their differences are central to understanding the offer.
We read selected official passages dated September 29, 2026, including the fuller treatment-plan pricing record. This is a Microdose Margin document review, not a purchase or pharmacy inspection. The publication's CoreAge promotional relationship does not supply a reason to favor or dismiss Lavender Sky's descriptions.
In this article
The custom pricing page actually names compounded tirzepatide
The treatment-plan pricing page explicitly identifies custom compounded tirzepatide injectables. It says the custom plan price includes medication, shipping and supplies, with provider and patient-team support through the described treatment duration. This is more specific than inferring the ingredient solely from a dual-agonist category.
The same record cautions that pharmacy formulations differ and that availability of a particular formulation cannot be guaranteed. A named custom category therefore supports the existence of an advertised offer, without identifying a reader's finished preparation. The Mochi review presents a different pharmacy-selection arrangement. The useful comparison is how each document connects a category to an actual supplier, rather than whether both webpages happen to display the same ingredient.
A monthly equivalent is expressly a comparison unit
Lavender's pricing explanation states that its tier plans are paid once upfront. The monthly figures are presented for comparing plans, rather than as a monthly payment schedule. The standard tier description concerns approximately eight to ten weeks of supply; extended plans describe longer prepaid periods.
Those periods are commercial record details, not a treatment timetable supplied by this review. The essential interpretation is that a table can express cost per month without promising monthly billing. The price-record guide helps distinguish the displayed unit from the actual payment event. We do not reproduce the tier selection instructions or reconstruct an individualized order. A complete quote would still need its selected plan, applicable pharmacy and upfront charge attached.
The brand service fee excludes the medicine
The brand-plan section describes a $25 monthly Standard service fee with medication purchased separately. The service page names Zepbound as an option when the person and provider determine it is appropriate, and describes prescription transmission and ongoing support as parts of that service.
This fee belongs to the brand-name arrangement, not the custom package that includes medicine. It would be misleading to assign $25 to the complete cost of tirzepatide or use the custom-plan inclusion language to enlarge the brand plan. Pharmacy price and availability remain separate. Sesame's records also separate a clinical subscription from medication charges, but its commitment structure is different. Similar exclusions do not make the two service agreements interchangeable.
The consultation FAQ needs reconciliation with the plan selected
The FAQ's payment section lists a $65 new-patient consultation and a $40 follow-up consultation, with medication charged separately. It describes no memberships or recurring billing. It also distinguishes custom plans that include medicine from Standard plans that exclude it.
The separate $25 monthly brand-service record should remain beside this FAQ instead of being silently overwritten by it. These passages may concern different arrangements, but the public review cannot decide which contract applies to an individual. This is not evidence that all charges necessarily accumulate, or that one page has been superseded. The uncertainty is precise: how does the selected care arrangement connect its consultation charge, plan fee and medicine payment? A service explanation tied to that arrangement would answer more than choosing whichever paragraph sounds simplest.
State coverage and communication format are different qualifications
The access FAQ describes a practice serving all states and Washington, DC, while explaining that pharmacies cannot ship every medicine to every state. It further limits asynchronous e-consults to eligible states and distinguishes them from live phone or video consultations. A nationwide practice statement therefore does not establish unrestricted access to each formulation or communication format.
The FAQ separately notes optional laboratory testing and provider discretion over prescriptions. Those statements describe Lavender's service, rather than a general conclusion that testing is unnecessary or that an advertised product suits everyone. The program-record comparison shows why geographic access, clinical selection and actual medicine availability need their own qualifications. None can be settled simply by reading the broadest coverage sentence.
A discussion of several routes is not one evidence claim
Lavender's information page discusses compounded oral and sublingual preparations as well as other forms. Its custom pricing record expressly names compounded injectable tirzepatide. That establishes different descriptions in the available paperwork, not proof that every route produces identical clinical results.
FDA's compounding FAQ explains why professional preparation does not amount to approval of the finished compound. Our compounding guide follows that distinction without turning website descriptions into medicine instructions. This review also does not adopt Lavender's broader cancer or comparative safety language as demonstrated program benefits. A provider's educational summary can be recorded as a claim while the evidence for a particular proposed preparation remains a separate question.
The remote-care limitation belongs in the final reading
The FAQ explains that the remote practice cannot provide emergency or same-day in-person care and that the assigned provider is not available every day. Unlimited-support language elsewhere should be interpreted alongside that specific limit, rather than as proof of continuous immediate clinician access.
Lavender's paperwork is informative when its pieces remain distinct: an explicit custom tirzepatide category, a separately paid brand medicine, different service-charge descriptions and pharmacy-dependent availability. The adverse-event reading guide addresses another boundary that reassuring access language cannot settle. This review has no verified consultation, supplied product or clinical response. It leaves those items open while preserving the actual plan distinctions that a headline monthly number would erase.
Sources behind this reading
- Lavender Sky Health: Treatment-plan pricing ↗Provider official service record · Checked 2026-09-29
- Lavender Sky Health: GLP-1 service plans ↗Provider official service record · Checked 2026-09-29
- Lavender Sky Health: Access, care and payment FAQ ↗Provider official service record · Checked 2026-09-29
- Lavender Sky Health: GLP-1 preparation information ↗Provider official service record · Checked 2026-09-29
- FDA: Compounding questions and answers ↗Regulatory primary explanation · Checked 2026-09-29